Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Grüllich

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Der Radiologe|September 6, 2017
[Immunotherapy as modern tumor treatment]C Grüllich
Der Urologe. Ausg. A|June 6, 2020
[First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology]A Zacharis, C Grüllich
Lupus|July 16, 2008
Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-upA Rückert, H Glimm, M Lübbert, et al.
Der Urologe. Ausg. A|April 19, 2020
[Targeted molecular therapy and immunotherapy for prostate cancer]C Grüllich, E Nößner, D Pfister, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Activity of immune checkpoint inhibition in platinum refractory germ-cell tumorsS Zschäbitz, F Lasitschka, D Jäger, et al.
FEBS Letters|March 7, 2001
Inhibition of 15-lipoxygenase leads to delayed organelle degradation in the reticulocyteC Grüllich, R M Duvoisin, M Wiedmann, et al.
Der Urologe. Ausg. A|October 7, 2020
[Immunotherapy and tyrosine kinase inhibitors in first-line treatment of metastatic renal cell carcinoma-Which strategy when?]G Mickisch, I Peters, C Grüllich, et al.
Der Urologe. Ausg. A|March 3, 2021
G Mickisch, I Peters, C Grüllich, et al.
Der Urologe. Ausg. A|May 4, 2019
[Molecular tumor board prostate cancer]A K Seitz, M M Heck, M W Kamer, et al.
Bone Marrow Transplantation|January 23, 2008
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantationC Grüllich, H Bertz, A Spyridonidis, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Der Radiologe|September 6, 2017
[Immunotherapy as modern tumor treatment]C Grüllich
Der Urologe. Ausg. A|June 6, 2020
[First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology]A Zacharis, C Grüllich
Lupus|July 16, 2008
Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-upA Rückert, H Glimm, M Lübbert, et al.
Der Urologe. Ausg. A|April 19, 2020
[Targeted molecular therapy and immunotherapy for prostate cancer]C Grüllich, E Nößner, D Pfister, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Activity of immune checkpoint inhibition in platinum refractory germ-cell tumorsS Zschäbitz, F Lasitschka, D Jäger, et al.
FEBS Letters|March 7, 2001
Inhibition of 15-lipoxygenase leads to delayed organelle degradation in the reticulocyteC Grüllich, R M Duvoisin, M Wiedmann, et al.
Der Urologe. Ausg. A|October 7, 2020
[Immunotherapy and tyrosine kinase inhibitors in first-line treatment of metastatic renal cell carcinoma-Which strategy when?]G Mickisch, I Peters, C Grüllich, et al.
Der Urologe. Ausg. A|March 3, 2021
G Mickisch, I Peters, C Grüllich, et al.
Der Urologe. Ausg. A|May 4, 2019
[Molecular tumor board prostate cancer]A K Seitz, M M Heck, M W Kamer, et al.
Bone Marrow Transplantation|January 23, 2008
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantationC Grüllich, H Bertz, A Spyridonidis, et al.
Pageof 3